220 related articles for article (PubMed ID: 29621658)
1. The incidence of occult malignancy following uterine morcellation: A ten-year single institution experience retrospective cohort study.
Mori KM; Abaid LN; Mendivil AA; Brown JV; Beck TL; Micha JP; Epstein HD; Goldstein BH
Int J Surg; 2018 May; 53():239-242. PubMed ID: 29621658
[TBL] [Abstract][Full Text] [Related]
2. Morcellation and the Incidence of Occult Uterine Malignancy: A Dual-Institution Review.
Picerno TM; Wasson MN; Gonzalez Rios AR; Zuber MJ; Taylor NP; Hoffman MK; Borowsky ME
Int J Gynecol Cancer; 2016 Jan; 26(1):149-55. PubMed ID: 26332395
[TBL] [Abstract][Full Text] [Related]
3. Occult Uterine Sarcoma and Leiomyosarcoma: Incidence of and Survival Associated With Morcellation.
Raine-Bennett T; Tucker LY; Zaritsky E; Littell RD; Palen T; Neugebauer R; Axtell A; Schultze PM; Kronbach DW; Embry-Schubert J; Sundang A; Bischoff K; Compton-Phillips AL; Lentz SE
Obstet Gynecol; 2016 Jan; 127(1):29-39. PubMed ID: 26646120
[TBL] [Abstract][Full Text] [Related]
4. Prevalence of occult pre-malignant or malignant pathology at the time of uterine morcellation for benign disease.
Von Bargen EC; Grimes CL; Mishra K; Wang R; Haviland MJ; Hacker MR; Carnevale JA; Estes AJ; Elkadry EA
Int J Gynaecol Obstet; 2017 May; 137(2):123-128. PubMed ID: 28170091
[TBL] [Abstract][Full Text] [Related]
5. Incidence of Occult Uterine Malignancy Following Vaginal Hysterectomy With Morcellation.
Wasson M; Magtibay P; Magtibay P; Magrina J
J Minim Invasive Gynecol; 2017; 24(4):665-669. PubMed ID: 28254678
[TBL] [Abstract][Full Text] [Related]
6. Risk of Undetected Cancer at the Time of Laparoscopic Supracervical Hysterectomy and Laparoscopic Myomectomy: Implications for the Use of Power Morcellation.
Perkins RB; Handal-Orefice R; Hanchate AD; Lin M; Paasche-Orlow MK
Womens Health Issues; 2016; 26(1):21-6. PubMed ID: 26701205
[TBL] [Abstract][Full Text] [Related]
7. Uterine leiomyosarcoma - incidence, treatment, and the impact of morcellation. A nationwide cohort study.
Skorstad M; Kent A; Lieng M
Acta Obstet Gynecol Scand; 2016 Sep; 95(9):984-90. PubMed ID: 27223683
[TBL] [Abstract][Full Text] [Related]
8. Morcellation of occult uterine malignancies: an Australian single institution retrospective study.
Tan A; Salfinger S; Tan J; Cohen P
Aust N Z J Obstet Gynaecol; 2015 Oct; 55(5):503-6. PubMed ID: 26314239
[TBL] [Abstract][Full Text] [Related]
9. Occult Leiomyosarcomas in a Canadian Province: A Retrospective Cohort Study.
Wu CQ; Woo LY; Giede KC; Thiel J; Karreman E; Rattray DD
J Obstet Gynaecol Can; 2019 Jan; 41(1):46-51. PubMed ID: 30341020
[TBL] [Abstract][Full Text] [Related]
10. The Morcellation Debate: The History and the Science.
Adelman MR
Clin Obstet Gynecol; 2015 Dec; 58(4):710-7. PubMed ID: 26512438
[TBL] [Abstract][Full Text] [Related]
11. Risk of morcellation of uterine leiomyosarcomas in laparoscopic supracervical hysterectomy and laparoscopic myomectomy, a retrospective trial including 4791 women.
Lieng M; Berner E; Busund B
J Minim Invasive Gynecol; 2015; 22(3):410-4. PubMed ID: 25460521
[TBL] [Abstract][Full Text] [Related]
12. Incidence of Occult Uterine Pathology in Women Undergoing Hysterectomy With Pelvic Organ Prolapse Repair.
Ackenbom MF; Giugale LE; Wang Y; Shepherd JP
Female Pelvic Med Reconstr Surg; 2016; 22(5):332-5. PubMed ID: 27171317
[TBL] [Abstract][Full Text] [Related]
13. Occult Uterine Malignancy at the Time of Sacrocolpopexy in the Context of the Safety Communication on Power Morcellation by the FDA.
Chang OH; Ferrando CA
J Minim Invasive Gynecol; 2021 Apr; 28(4):788-793. PubMed ID: 32681994
[TBL] [Abstract][Full Text] [Related]
14. Practice patterns and postoperative complications before and after US Food and Drug Administration safety communication on power morcellation.
Harris JA; Swenson CW; Uppal S; Kamdar N; Mahnert N; As-Sanie S; Morgan DM
Am J Obstet Gynecol; 2016 Jan; 214(1):98.e1-98.e13. PubMed ID: 26314519
[TBL] [Abstract][Full Text] [Related]
15. Risk of Occult Uterine Sarcoma in Presumed Uterine Fibroids.
Cui RR; Wright JD
Clin Obstet Gynecol; 2016 Mar; 59(1):103-18. PubMed ID: 26645385
[TBL] [Abstract][Full Text] [Related]
16. Incidence of occult leiomyosarcoma in presumed morcellation cases: a database study.
Rodriguez AM; Zeybek B; Asoglu MR; Sak ME; Tan A; Borahay MA; Kilic GS
Eur J Obstet Gynecol Reprod Biol; 2016 Feb; 197():31-5. PubMed ID: 26699101
[TBL] [Abstract][Full Text] [Related]
17. Unexpected uterine smooth muscle tumor of uncertain malignant potential and sarcoma: A single center cohort study in South Korea.
Han AKW; Hong K; Kim M; Kim MK; Kim ML; Jung YW; Yun BS; Seong SJ
Taiwan J Obstet Gynecol; 2020 Mar; 59(2):275-281. PubMed ID: 32127150
[TBL] [Abstract][Full Text] [Related]
18. Incidence of Leiomyosarcoma at Surgery for Presumed Uterine Myomas in Different Age Groups.
Rey Valzacchi GM; Rosas P; Uzal M; Gil SJ; Viglierchio VT
J Minim Invasive Gynecol; 2020; 27(4):926-929. PubMed ID: 31260748
[TBL] [Abstract][Full Text] [Related]
19. Incidence of Malignancy and Myoma Variants at Surgery for Presumed Benign Symptomatic Myomas.
Damasco MR; Chan PK; Slonim M; Ang WC; Healey MG
J Minim Invasive Gynecol; 2017; 24(4):659-664. PubMed ID: 28216458
[TBL] [Abstract][Full Text] [Related]
20. Incidence of sarcoma in patients undergoing hysterectomy for benign indications: a population-based study.
Multinu F; Casarin J; Tortorella L; Huang Y; Weaver A; Angioni S; Melis GB; Mariani A; Stewart EA; Laughlin-Tommaso SK
Am J Obstet Gynecol; 2019 Feb; 220(2):179.e1-179.e10. PubMed ID: 30447212
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]